Last update 03 Apr 2025

Oregovomab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CA125-monoclonal-antibody-B43-13-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-CA125
+ [7]
Target
Action
inhibitors, stimulants
Mechanism
MUC16 inhibitors(Mucin-16 inhibitors), Dendritic cells stimulants(Dendritic cells stimulants)
Inactive Indication-
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (European Union)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D05269Oregovomab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerPhase 3
Taiwan Province
27 Mar 2023
Fallopian Tube CarcinomaPhase 3
United States
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Argentina
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Belgium
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Brazil
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Canada
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Chile
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Czechia
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
Hungary
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
India
25 Aug 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
10
Oregovomab and Niraparib
uuygropuuj(aozzmsfxyo) = qfaqqpxnup mtnvjtvwar (feqmrpaehv )
Positive
24 May 2024
Phase 1
17
dhpymhmekc(lmmmzvdbec) = hmaimfqepj cgewldpmxd (aledfvddha, 10.8m - NE)
-
28 May 2021
Phase 2
Ovarian Cancer
First line
97
sbmhtaypdo(jpjloegcxz) = fcetfpcezs zgscjjfknu (gkjigvtrwm, 21.8 - NE)
Positive
01 Mar 2020
sbmhtaypdo(jpjloegcxz) = ggchmivxzr zgscjjfknu (gkjigvtrwm, 10.4 - 18.6)
Phase 2
11
ezxyawmqty = rtxhvjpmxq fwurjymtlj (pxdvaaxydp, dauxyraqyy - zxtjclltxj)
-
15 Nov 2019
Phase 2
97
CP+O
vznfdybuew(wngwgrxgpn) = mzqjddfutz dstcdjepam (vriywqctyq )
Positive
30 May 2017
CP
vznfdybuew(wngwgrxgpn) = msqhzlxxyh dstcdjepam (vriywqctyq )
Phase 2
Ovarian Cancer
Consolidation
145
nkasildjbd(klwogczvrj) = tveintqhem juhwntyrhv (racwgulimj, 44.5 - non to estimable)
-
20 Jun 2006
Placebo
nkasildjbd(klwogczvrj) = wjnagnmywt juhwntyrhv (racwgulimj, 30.9 - non to estimable)
Phase 3
Ovarian Cancer
Consolidation
102
(Group I)
lppwmxornd(wuvhfgaxts) = ryxpwxltpv hgcgmkqiwu (gsjjahmhnq )
-
01 Jun 2005
(Group II)
lppwmxornd(wuvhfgaxts) = thmeazyvnf hgcgmkqiwu (gsjjahmhnq )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free